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C A N C E R
Tumor-specific cytolytic CD4 T cells mediate immunity 
against human cancer
Amélie Cachot1*, Mariia Bilous1,2*, Yen-Cheng Liu3*, Xiaokang Li3, Margaux Saillard1, 
Mara Cenerenti4,5, Georg Alexander Rockinger1, Tania Wyss1,2, Philippe Guillaume1, 
Julien Schmidt1, Raphaël Genolet1, Giuseppe Ercolano4,5, Maria Pia Protti6, Walter Reith4, 
Kalliopi Ioannidou7, Laurence de Leval7, Joseph A. Trapani8, George Coukos1,  
Alexandre Harari1, Daniel E. Speiser1, Alexander Mathis9,10,11, David Gfeller1,2, Hatice Altug3, 
Pedro Romero1†, Camilla Jandus4,5†‡§
CD4 T cells have been implicated in cancer immunity for their helper functions. Moreover, their direct cytotoxic 
potential has been shown in some patients with cancer. Here, by mining single-cell RNA-seq datasets, we 
identified CD4 T cell clusters displaying cytotoxic phenotypes in different human cancers, resembling CD8 
T cell profiles. Using the peptide-MHCII-multimer technology, we confirmed ex vivo the presence of cytolytic 
tumor-specific CD4 T cells. We performed an integrated phenotypic and functional characterization of these cells, 
down to the single-cell level, through a high-throughput nanobiochip consisting of massive arrays of picowells 
and machine learning. We demonstrated a direct, contact-, and granzyme-dependent cytotoxic activity against tumors, 
with delayed kinetics compared to classical cytotoxic lymphocytes. Last, we found that this cytotoxic activity was 
in part dependent on SLAMF7. Agonistic engagement of SLAMF7 enhanced cytotoxicity of tumor-specific CD4 
T cells, suggesting that targeting these cells might prove synergistic with other cancer immunotherapies.
INTRODUCTION
Antigen-driven activation of naïve CD4 T cell precursors leads to 
their expansion and differentiation into a wide spectrum of func-
tionally defined subsets (1). The diverse functional polarization of 
CD4 T cells [e.g., T helper cell 1 (Th1), Th2, Th17, and regulatory 
T cell (Treg)] was proven to affect tumor immunity distinctly, playing 
a notable role in the patients’ clinical outcome (2–9). While several 
studies and clinical trials have highlighted the helper activities of 
CD4 T cells (2, 3, 5–9), the evaluation of direct cytolytic functions of 
these cells against cancer has been demonstrated in some patients.
CD4 T cells with cytotoxic functions (Th-CTX) have been found 
in certain viral infections (10–14), malaria (15), and autoimmune 
disorders (16–18). Their presence was associated with either the es-
calation of the disease (19) or the induction of protective immunity. 
However, the highly variable combinations of surface biomarkers 
used to define Th-CTX [including CRTAM (20), CX3CR1 (11), 
CD103 (21), NKG7 (22), CD29 (19), CD38 (23), and NKG2D (24)], 
without the assessment of their direct cytolytic activity, render com-
parisons on the functionality of this unique cell subset difficult across 
different studies. Furthermore, the differentiation pathway of Th-CTX 
remains poorly understood. Various transcription factors including 
T-bet (T-box transcription factor TBX21), Eomes (11, 25–27), Runx3, 
ThPOK, (28), Hobit (29), and Blimp-1 (30) have been suggested as 
the upstream inducers for cytolytic-related functions of Th-CTX.
In cancer, most of the data on Th-CTX stem from preclinical 
models of solid tumors. The in vivo differentiation of naïve tumor- 
specific CD4 T cells into Th1 cytolytic T cells was sufficient to 
induce the regression of established tumors in a major histocom-
patibility complex class II (MHCII)–restricted manner (31). In 
addition, adoptive transfer of CD4 T cells in combination with 
CTLA-4 (Cytotoxic T-Lymphocyte Antigen 4) blockade (32) or ago-
nistic anti-CD137 antibody immunotherapy (33) into lymphopenic 
mice resulted in potent rejection of large vascularized melanomas, 
independent of other immune cells and in an MHCII-restricted manner.
In patients, Th-CTX were initially reported in patients with 
B-CLL (B-cell chronic lymphocytic leukemia) (34). More recently, 
cytotoxic CD4 T cells were identified in four patients with melanoma 
undergoing anti–CTLA-4 treatment. Antigen-specific CD4 T cells 
recognized tumor cell lines and exerted direct lysis of autologous 
NY-ESO-1+ (New York esophageal squamous cell carcinoma 1) 
melanoma cells in an MHCII- dependent fashion (25). Similarly, 
in vitro OX40 engagement by three human-derived antigen- specific 
CD4 T cell lines exhibited an enhanced antitumor function against 
melanoma cell lines and a higher EOMES and T-bet expression, 
arguing for a tumoricidal capacity as observed in the mouse counter-
part (26). Recently, the cytolytic function of CD4 T cells was associated 
with an interleukin-2 (IL-2)/Blimp-1/granzyme B axis, whereby Tregs 
acted as suppressors by sequestering IL-2 from the tumor bed. In 
this setting, T-bet expression was required for the polyfunctionality 
but not for the cytotoxicity of tumor-reactive CD4 T cells (30). 
Furthermore, it was shown that basal in situ MHCII expression, 
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but not MHCI, was sufficient to segregate responders from nonre-
sponders in advanced melanoma patients treated with an anti–PD-1 
(Programmed cell death protein 1) antibody (35), arguing for a poten-
tial direct contribution of cytotoxic CD4 T cells to tumor elimination 
in patients. Another study in bladder cancer recently reported on high-
ly heterogeneous CD4 T cell transcriptomic states within tumors, with 
cytotoxic signatures being predictive of response to PD-1 blockade (36).
Here, we aimed at assessing the presence, rate, and cytotoxic 
function of tumor-specific Th-CTX directly in patients with cancer. 
We capitalized on published single-cell transcriptomic analyses of 
patient samples, integrated with the direct phenotypic and func-
tional characterization of clonal, tumor-specific CD4 T cell popula-
tions, using peptide-MHCII (pMHCII) multimers and a novel 
high-throughput single-cell cytotoxicity assay in picowell arrays. 
The direct tumor cell killing by cytolytic tumor-specific CD4 T cells 
in the arrays was monitored in a high-throughput manner by 
combining multichannel time-lapse microscopy with deep neural 
networks. Our work provides a deep characterization of human 
Th-CTX in cancer and supports their role in tumor immunity.
RESULTS
The transcriptomic signature of tumor-infiltrating cytolytic 
CD4 T cells from patients with melanoma
To define a putative signature of cytolytic CD4 T cells, we mined a 
publicly available single-cell RNA sequencing (scRNA-seq) dataset 
from 32 tumor biopsies of patients with advanced melanoma 
(n = 12,850 single cells in total) (37). We used these data to generate 
a robust transcriptional map of Th-CTX and to determine potential 
candidate markers linked with their cytotoxic function in cancer.
Within the total tumor-infiltrating lymphocytes (TILs) (n = 8162), 
the CD3+CD4+CD8− population was defined as “CD4 T cells” 
(n = 2333, 28.6%), while the CD3+CD8+CD4− expressing popula-
tion, used as control, was annotated as “CD8 T cells” (n = 5829, 
71.4%) (Fig. 1A). Using an unsupervised clustering of the CD4 
T cell population, further diversity was found within this group 
with the identification of four major cell states (Fig. 1B). Clusters 
were annotated on the basis of the expression of known genes. One 
cluster showed high expression of FOXP3 (forkhead box P3), TIGIT 
(T-cell immunoreceptor with Ig and ITIM domains), and IL-2RA 
and was defined as CD4_Regulatory cluster (n  =  1109). Another 
cluster was enriched in genes linked with memory and survival such 
as IL-7R, T cell factor 7, and CCR7 and was referred to as CD4_Mem-
ory cluster (n = 599). A third cluster demonstrated increased ex-
pression of genes implicated in proliferation such as MKI67, ZWINT, 
and TYMS, suggesting that it represents a CD4_Cycling cluster 
(n = 180). The fourth cluster was enriched in genes linked to ef-
fector/cytolytic functions in CD4 T cells such as PRF1, GZMA, 
GZMB, GZMH, GZMK, GZMM, GNLY, FASLG, NKG7, SLAMF7, 
PLEK, and KLRG1 and was annotated as CD4_Cytolytic cluster 
(n  =  445) (Fig.  1B and fig. S1A). Notably, each of the clusters 
contained cells from different patients, indicating that clusters and 
expression states are conserved across patients and do not represent 
patient-specific subpopulations or batch effects, although they do 
vary in their relative proportions (Fig. 1C).
Further, gene ontology (GO) enrichment analysis of the gene 
signature of each cluster supported the distinct role of these CD4 
T cell populations (Fig. 1D). The CD4_Regulatory signature was en-
riched in pathways related to general leukocyte homeostasis as well 
as Treg differentiation. The CD4_Memory cluster was enriched in 
pathways promoting the activation and proliferation of leukocytes 
and associated with response to cytokines and migration of cells. 
The CD4_Cycling signature demonstrated a major cytoskeleton and 
nuclear reorganization bias, linked with cell cycle and division. The 
lytic granule genes identified in the scRNA-seq analysis were exclu-
sively up-regulated in the CD4_Cytolytic signature, at similar ex-
pression levels as in the CD8 cluster (Fig. 1, E and F), with further 
enrichment of an extensive defense response axis, mostly built on 
cytolysis related GO pathways. The observed CD4_Cytolytic cluster 
specifically showed higher expression of genes previously linked to 
effector/cytolytic functions in CD4 T cells, such as CRTAM (20), NKG7 
(22), KLRG1 (38), and CST7 (Cystatin F) (Fig. 1E). Only a modest FasL 
(Fas Ligand) increase, but no increase of TRAIL death receptor/ligand 
pathway, was apparent in the CD4_Cytolytic cluster (Fig. 1, E and F).
The cytolytic CD4 T cell cluster included also an increased ex-
pression of CCL5, CCL4, and CCL4L1/2 (Fig. 1E), which was addi-
tionally evidenced by the enrichment of the lymphocyte chemotaxis 
and cellular response to interferon- (IFN) pathways in the GO-
based analysis (Fig. 1D). None of the known master transcription 
factors was specifically overexpressed in the CD4_Cytolytic cluster 
(Fig. 1, E and F). RUNX3 (RUNX family transcription factor 3) and 
BLIMP-1 (B lymphocyte-induced maturation protein-1) (30) did not 
correlate with a cytolytic potential. A modest enrichment of EOMES, 
an upstream inducer of cytolytic-related molecules, in combina-
tion with T-bet (11, 25–27), was observed within the CD4_Cytolytic 
cluster, despite general low transcript expression.
Overall, these results suggest the in vivo presence of Th-CTX 
CD4 T cells infiltrating tumor tissues of patients and provide detailed 
gene signatures characterizing them.
Direct ex vivo detection of tumor-specific cytolytic CD4 
T cells in patients with melanoma
To gain insight into the cytolytic features of antigen-specific CD4 
T cells directly ex vivo and to validate the gene signature obtained by 
the scRNA-seq analysis (Fig. 1), we used peptide-MHCII multimers 
(39). We quantified and isolated NY-ESO-187–99/DR7-specific CD4 
T cells ex vivo from both peripheral blood lymphocytes (PBLs; nine 
samples) and TILs/tumor-infiltrated lymph nodes (TILNs) (eight 
samples), respectively. We observed homogeneous CD4 T cell fre-
quencies in PBLs in comparison to more variable infiltration within 
the TIL/TILN samples (Fig. 2A). Similarly, the presence of NY-
ESO-187–99/DR7 CD4 T cells was detected in eight of nine blood 
samples in contrast to the tumor, where five of eight samples 
showed multimer+ cells (Fig. 2B). Because of the limited number of 
cells that could be recovered after flow cytometry–based sorting, we 
focused on the assessment of selected genes that were either enriched 
within the scRNA-seq CD4_Cytolytic cluster (Fig. 1D) or previously 
associated in the literature with cytolytic capacity in CD4 T cells 
(28, 30). Granzyme B was higher in NY-ESO-187–99/ DR7 CD4 T cells 
present in the blood compared to the tumor bed, while perforin, 
granzyme A, and BLIMP-1 showed an opposite distribution pattern. 
RUNX3 expression was relatively scarce but stable in the two groups, 
similarly to granulysin. If compared to multimer-negative circulating 
CD4 T cells and to CD8 T cell subsets (naïve and non-naïve CD8 
T cells) isolated from the same patients, NY-ESO-187–99/DR7 CD4 
T cells show cytolytic-related transcript similar to antigen-primed 
CD8 T cells (fig. S1B). Overall, the direct ex vivo detection of tumor- 
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Fig. 1. The transcriptomic signature of tumor-infiltrating cytolytic CD4 T cell from patients with melanoma. (A) Frequency of CD4 and CD8 TIL among all CD3+ 
T cells collected from 32 patients with melanoma. (B) t-distributed stochastic neighbor embedding (tSNE) two-dimensional (2D) plot of scRNA-seq data representing all 
CD3+CD4+CD8− T cells. Colors correspond to the four clusters discriminating the cytolytic (blue, n = 445), memory (green, n = 599), cycling (yellow, n = 180), and regulatory 
(gray, n = 1109) subsets. (C) The relative CD4 cluster abundance within the CD3+CD4+CD8− T cells in each patient. (D) GO-based analysis illustrating enrichment of 
pathways observed in each of the four distinct CD4 clusters. (E) Bubble plot of the top 30 up-regulated genes in the CD4_Cytolytic cluster. (F) Violin plots showing the 
distribution of gene expression levels for selected cytolysis related and master transcription factor genes across the four CD4 T cell clusters (regulatory in gray, memory 
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in the circulation but also within the tumor argues for their potential 
functional role in vivo (Fig. 2C).
The cytolytic activity of CD4 T cells against tumors requires 
MHCII expression in cancer cells. Although MHCII is not often 
constitutively expressed in solid tumors, it is induced in diverse 
cancer types (40) with around 30% of melanoma cases exhibiting 
around 10% of MHCII+ cells in the tumor bed (35).
To evaluate the presence of MHCII in melanoma directly in situ, 
immunostaining for HLA-DR was performed on metastatic mela-
noma sections of 18 patients. MHCII expression in the tumor cells 
was detected in 5 of 18 cases, and the percentage of positive tumor 
cells ranged from 1.2 to 8.4% (Fig. 2D). HLA-DR positivity was also 
detected on cells within the tumor stroma (Fig. 2D). Accordingly, 
in vitro experiments using IFN or/and tumor necrosis factor– 
(TNF) treatment of melanoma cell lines, to mimic a proinflamma-
tory microenvironment, showed a significant enhancement of 
MHCII expression after treatment in most of the tested lines 
(Fig. 2E), arguing for potential Th-CTX–tumor cell interactions in 
immune-infiltrated tumor regions.
Delayed but direct cytolytic capacity of NY-ESO-187–99/DR7 
CD4 T cells against melanoma cell lines
To date, the absence of a functional assessment of their cytolytic 
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Fig. 2. Direct ex vivo detection of tumor-specific cytolytic CD4 T cells in patients with melanoma. (A) Ex vivo frequency of CD4 T cells among PBLs and TILs/TILNs in 
patients with melanoma. (B) Representative examples (left) and summarizing graphs (right) of ex vivo pMHCII multimer staining of CD4 T cells specific for NY-ESO-187–99/
DR7 obtained in PBL and TIL/TILN of HLA-DR7+ patient samples. (C) Quantitative reverse transcription PCR (RT-PCR) analysis of the indicated transcripts in ex vivo sorted 
NY-ESO-187–99/DR7 CD4 T cells isolated either from spell peripheral blood (PB) or TILs/TILNs. (D) Multispectral imaging assessment of MHCII expression directly in situ on 
18 metastatic melanoma tissues. Representative examples of two cases (a) with expression of HLA-DR quantified to 5.8% of tumor cells within the SOX-10+ tumor 
niche (white arrows) and (b) lower expression of HLA-DR in 2.07% of the SOX-10+ tumor cells (white arrows). Stromal cells expressed HLA-DR, pointed by yellow arrow-
heads. The insets illustrate high-power images. The MSI were acquired using a 20× objective of the Vectra 3.0 imaging system. Scale bar, 50 m. (c) Graph of frequency 
of HLA-DR–positive cells expressed in percentages, in the tumor SOX-10+ classified tissue category versus the stroma. DAPI, 4′,6-diamidino-2-phenylindole. (E) In 
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across different models (11, 20, 22, 23, 29). To tackle this issue, we 
isolated tumor-specific CD4 T cell clones from ex vivo multimer+ 
sorted cells from patient samples. To discriminate helper (Th) 
versus cytolytic (Th-CTX) profiles, we used the standard 4 hours 
51Chromium release cytotoxic assay on each clone (fig. S2A), in the 
presence of tumor cells either pretreated with IFN or stably CIITA 
(Class II Major Histocompatibility Complex Transactivator) trans-
duced, to increase the MHCII expression. The CIITA-transduced cell 
lines showed a more homogeneous and high expression of MHCII, 
as compared to wild-type (WT) or IFN-treated tumor cells 
(Fig. 3A). As expected, no specific lysis of NY-ESO-1− cells oc-
curred in the absence of the specific peptide, independently of the 
MHCII expression levels on target cells (Fig. 3B). A high level of 
lysis, up to 46% at the highest 30:1 E:T (effector-to-target) ratio, of 
CIITA-transduced tumor cells loaded with the cognate peptide was 
observed (Fig. 3B). Significantly, lower levels of specific lysis were 
measured when IFN-treated and WT tumor cells were used as 
targets (Fig. 3B). The use of an HLA-matched, endogenously ex-
pressing NY-ESO-1 tumor cell line coincubated with the CD4 
T cell clones showed similar but delayed specific lysis occurring after 
24 hours in a proportion of the tested clones, demonstrating that 
peptide-specific CD4 T cell clones recognize a naturally processed 
epitope on tumor cells (Fig. 3C). This effector capacity was not lim-
ited to one epitope, as similar assays conducted on additional CD4 
T cell clones specific for the Mage-A3111–125/DP4 and Mage-A3243–258/
DP4 epitopes showed a similar pattern of lysis (fig. S2B).
Next, to estimate the cytotoxicity kinetics of individual cytolytic 
CD4 T cells, a novel high-throughput single-cell tumor recognition 
assay was developed. This consists of a time-lapse imaging platform 
for profiling dynamic cell-cell interactions at the single-cell level. 
It combines large arrays of microfabricated picowells [made of 
polydimethylsiloxane (PDMS)] with automated time-lapse fluores-
cence microscopy. The microfabricated chip consists of 12 columns 
and 18 rows of blocks, and each of the block contains 99 square 
picowells, thus providing, at full capacity, 21,384 wells in total (see 
fig. S2D for the chip configuration). The picowells (35 m by 35 m 
by 50 m) that have a confinement volume less than 65 pl allow 
close interaction between a few effector and target cells in spatially 
confined volumes. At the same time, their microarray configuration 
provides a potent tool to monitor cytotoxicity of thousands of 
T cells simultaneously at the single-cell level (41, 42). To perform 
the assay, suspensions of prelabeled CIITA-transduced tumor cells 
(PKH26, red) and tumor-specific T cells (CellTrace Violet, blue) 
were sequentially and manually loaded into the picowells, followed 
by immersion in media containing the specific peptide as well as a 
live-dead green apoptotic staining cocktail. The phenotype and 
state of the cells in each well were determined with four channels 
[bright field, AF488, tetramethyl rhodamine isothiocyanate (TRITC), 
and BV421] imaged at a 10-min interval for 24 hours. In particular, 
viable T cells are labeled with blue (BV421), viable and dead target 
cells in red (TRITC), and red and green (TRITC + AF488), respec-
tively (Fig. 3D). The picowell array–based time-lapse microscopy 
generates a large amount of imaging data. To perform automated 
quantitative analysis of independent T cell tumor cell interactions, 
acquired images were processed by using an adapted version of 
DeepLabCut v2.2, an open-source deep learning toolset (43). The 
algorithm enables discriminating the diverse E:T ratios (e.g., dis-
carding the empty/overcrowded wells or wells with only one cell 
type) and to analyzing the specificity of target cell lysis induced by 
tumor antigen–specific CD4 T cells. The deep convolutional network 
can efficiently extract the coordinates of the key features, including 
well boundaries, viable, and apoptotic tumor or T cells, in the entire 
video based on manually annotated data from a few frames (see 
Materials and Methods and fig. S2E for a representative movie). 
Tumor-specific CD8 T cells were used as positive cytolytic controls 
(Fig. 3, F to H, and fig. S2C). Before testing cytotoxicity of individual 
antigen-specific T cells and to gain insight on the overall cytotoxic 
capacity of CD4 T cells, we used MHCII–expressing targets, loaded 
with the superantigen Staphylococcus enterotoxin B (SEB). We 
observed similar capacities of CD4 and CD8 T cells in target cell 
killing in this setting (fig. S2F).
Next, we moved to tumor-specific T cell evaluation. Results from 
five independent experiments demonstrated that antigen-specific 
CD4 and CD8 T cells were able to lyse tumor cells directly at a 
1:1 ratio, reaching 30.2 and 71.6% of lysed tumor cells by CD4 or CD8 
T cells, respectively (Fig. 3F). Tumor-specific T cells exhibited 
functional heterogeneity at identical E:T ratios among different 
picowells. Despite the detected contacts, the interactions between 
target and CD4 T cells either resulted in specific lysis or failed to 
induce apoptosis (Fig. 3E). Quantification of the average percentage 
of tumor apoptosis showed a tendency toward a higher lytic capacity 
in the presence of an excess of target over CD4 T cells. The observed 
pattern of lysis “E<T” > “E:T” > “E>T” was in line with previous 
work performed on CD8 T and natural killer (NK) cells where 
negative ratios were favorable to increase apoptosis of the targets 
(44, 45). Further temporal analysis of the onset of tumor cell apop-
tosis (Fig. 3, G and H) revealed that cytolytic activity of CD4 T cells 
started after a few minutes of initiation of coculture and persisted 
until 15 to 20 hours with an average time of 5.3 hours for the 1:1 ratio. 
Tumor antigen–specific CD8 T cells demonstrated a faster killing 
window with an average time of 2.4 hours. Further, the fact that 
“E<T” ratios showed a delayed time of killing but a higher rate of 
specific lysis implies a burst of T cells’ lytic capacity. Independent 
kinetics assessment of 121 picowells presenting a single CD4 T cell 
outnumbered by targets cells revealed sequential fluorescence peaks 
of the caspase-3/7 reagent, suggesting the serial engagement in 
multiple killing activities by some Th-CTX (Fig. 3I).
The release of cytolytic molecules is mainly responsible 
for the cytolytic potential of tumor-specific CD4 T cells
To understand the molecular pathways involved in the cytotoxicity 
of CD4 T cells, cytokines and cytolytic related molecules produced 
by NY-ESO-187–99/DR7 CD4 T cell clones were analyzed after a 
6-hour coculture with titrated concentrations of peptides. All tested 
clones presented a relatively low level of perforin, granzyme K, and 
granzyme M without significant differences between Th and Th-
CTX. In contrast, both populations showed high production of 
granzyme A with around 78.8 or 87.5% in Th or Th-CTX, respec-
tively. Granzyme B and granulysin loads were significantly in-
creased within Th-CTX CD4 T cell clones in comparison to the 
helper ones (Fig. 4A). Notably, granzyme B expression was also 
significantly enhanced at the transcriptomic level, suggesting a 
potential key role of this granzyme in the lytic capacity of the CD4 
T cells (Fig. 4B). These results were in line with the observed signif-
icant enrichment of lytic granules within the CD4_Cytolytic cluster 
in the ex vivo scRNA-seq analysis (Fig. 1D). Accordingly, tumor 
recognition assays performed in the presence of concanamycin 
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Fig. 3. Delayed but direct cytolytic capacity of NY-ESO-187–99/DR7 CD4 T cells against melanoma lines. (A) Representative histogram of MHCII expression of a WT 
(light gray), IFN𝛾-treated (dark gray), and CIITA-transduced (black) tumor cell lines. FMO is shown as dashed line. (B) Cumulative analysis of 51Chromium release assays 
conducted with tumor cell lines transduced with CIITA, IFN𝛾 treated, or unmanipulated, pulsed or not with a specific peptide, and coincubated with PB (peripheral blood)– 
derived CD4 T cell clones. (C) Summary of the specific lysis obtained using a tumor cell line endogenously expressing NY-ESO-1 cocultured with PB-derived NY-ESO-187–99/
DR7–specific CD4 T cell clones. Statistics were performed using nonparametric unpaired Kruskal-Wallis test (B) and matched-pairs signed-rank test (C). P values of <0.05 
were considered statistically significant. (D) Single-cell tumor recognition assay using time-lapse imaging microscopy in picowell grids: Schematic illustration of the data 
analysis with deep learning approaches including the network training (1), video analysis for features extraction (2), and data screening and MFI analysis. DNN, deep 
neural network. (E to H) Fluorescently labeled CIITA–transduced tumor cell line pulsed with a specific peptide was cocultured with PB-derived NY-ESO-187–99/DR7 CD4 T 
cells in a PDMS picowell array. (E) Representative time series data at 0 and 20 hours of an enlarged view of two picowells showing CD4 T cells (blue), tumor cells (red), and 
the caspase-3/7 pathway reagent identifying cells undergoing apoptosis (green). (F) Cumulative analysis of average percentage of specific lysis, (G) real-time dynamic MFI 
of the tumor apoptosis, (H) the time of the lysis defined at a single cell level, and (I) time of the consecutive lytic events in wells with target cells outnumbering T cells. 
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Fig. 4. The release of cytolytic molecules is mainly responsible for the cytolytic potential of tumor-specific CD4 T cells. PB-derived NY-ESO-187–99/DR7–specific CD4 
T cell clones were discriminated as Th or Th-CTX based on results obtained with a standard 4-hour 51Chromium release assay. (A) Representative example (top) and 
cumulative analysis (bottom) of the production of perforin (PRF1), granzymes (GZMA, GZMB, GZMK, and GZMM), and granulysin (GNLY) by NY-ESO-187–99/DR7–specific CD4 
T cell clones. (B) Quantitative RT-PCR (qRT-PCR) analysis of the indicated transcripts in PB-derived NY-ESO-187–99/DR7 CD4 T cell clones. (C) Standard 4-hour 51Chromium 
release assay was conducted with a CIITA-transduced tumor cell line pulsed or not with a specific peptide. Release of perforin was blocked by a 2-hour pretreatment of 
antigen-specific CD4 T cells with CMA (100 nM). Results are expressed as percentage of specific lysis of the target cells at 30:1 E:T ratio. Statistics were performed using 
nonparametric unpaired Kruskal-Wallis test. (D) Average dose-response curves and Bmax (maximal response), EC50 values of IFN, TNF, IL-13, and IL-17a induced by 
titrated concentrations of NY-ESO-187–99 peptide by PB-derived NY-ESO-187–99/DR7–specific CD4 T cell clones. (E) Quantitative RT-PCR analysis of the indicated transcripts 
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pump, leading to the degradation of the perforin present within 
the vacuoles containing granzymes, exhibited a marked de-
crease of lysis (Fig. 4C and fig. S2B). Cytotoxicity was contact de-
pendent, because the use of a transwell completely abolished target 
cell killing (fig. S3A, left graph). In line with these observations, 
CD107a was up-regulated during the cytotoxic process in Th-CTX 
(fig.S3A, right graphs) and the use of the membrane-soluble 
Compound 20, a specific granzyme B inhibitor, significantly reduced 
target cell lysis (fig. S3B). As a complete abrogation of lysis was not 
achieved neither upon CMA nor Compound 20 exposure, a possi-
ble role of alternative apoptotic pathways was considered, including 
Fas and TRAIL. However, no significant differences in the Fas or 
TRAIL expression were detected between Th and Th-CTX clones 
(fig. S3C).
To define whether the cytotoxic and helper potentials were 
mutually exclusive, we profiled all clones for their capacity to secrete 
Th-prototypic cytokines for Th1 (IFN and TNF), Th2 (IL-13), 
and Th17 (IL-17a) profiles (Fig. 4D). Bmax (maximum cytokine 
production) values showed a generally higher type 1 cytokine (IFN 
and TNF) production compared to IL-13 and IL-17a, with this 
tendency being enhanced in the Th-CTX (Fig. 4D). Median effec-
tive concentration (EC50) of IFN, TNF, and IL-13 production 
showed similar values in all clones tested, irrespective of their cyto-
toxic capacities. EC50 of IL-17a could not be assessed as several 
clones were negative for this cytokine. The cytotoxic function was 
not linked to the expression of a specific master transcription factor, 
because no distinction was observed among the clones tested, with 
the exception of RUNX3 up-regulation in Th-CTX cells in compar-
ison to the helper clones (Fig. 4E). These results suggest a polyfunc-
tional phenotype of cytolytic tumor-specific CD4 T cell clones with 
the concomitant production of cytokines, in addition to their acqui-
sition of cytolytic functions. Hence, the ultimate cytotoxic potential 
might depend on additional intrinsic differences within the CD4 
T cells themselves, such as variable T cell receptor (TCR) repertoires 
and affinities, or distinct expression of activating and inhibitory 
receptors.
TCR repertoires of Th and Th-CTX CD4 T cells are polyclonal
We sequenced the TCR  and  chains of 32 NY-ESO-187–99/DR7 
CD4 T cell clones isolated from three peripheral blood mononuclear 
cells (PBMCs) of patients and defined as either Th or Th-CTX 
based on the cytotoxic assays presented in Fig. 3. NY-ESO-187–99/
DR7 CD4 T cell clones showed diverse clonally distributed TCRs, 
with the presence of 16 distinct clonotypes. However, variability in 
the number of clonotypes was high across patients, with highest 
polyclonality observed for patient LAU1293 (Fig. 5A). The relative 
abundance of each clonotype as a whole, within Th or Th-CTX 
clones, was also variable in the three patients (Fig. 5B). For each 
patient, shared but also distinct TCR  and  chains were identified 
among Th and Th-CTX (Fig. 5, A and C). Notably, the assessment 
of the MFI (mean fluorescence intensity) membrane expression of 
TCR showed similar values in all clones tested, irrespective of their 
cytotoxic capacities (fig. S3D), arguing for a minor impact of the 
TCR in functional divergence.
SLAMF7 as candidate to increase cytolytic potential 
of tumor-specific CD4 T cells
To screen for potential surface markers of Th-CTX, we exploited 
the CD4_Cytolytic cluster that we determined in the scRNA-seq 
dataset. We identified the SLAMF7 (Signaling lymphocytic acti-
vation molecule F7) as being predominantly expressed in the 
CD4_Cytolytic cluster and, to a lesser extent, PD-1 as being mainly 
expressed in cycling and cytolytic clusters (Fig. 6A). Homophilic 
SLAMF7 interactions in NK cells have been reported to lead to the 
activation of their natural cytotoxicity (46). Moreover, the engage-
ment of the SLAMF7 axis was associated with the partial rescue of 
effector functions in NK and CD8 T cells in patients with lupus 
erythematosus and multiple myeloma, correlating with beneficial 
clinical effects (46, 47). In addition, the expression of PD-L1 (Pro-
grammed death-ligand 1) and PD-L2  in melanoma cell lines in a 
proinflammatory environment (fig. S4) led us to investigate the SLAMF7 
and PD-1 distribution in correlation to cytolysis-related molecules.
In addition to SLAMF7 and, to a lower extent, of PD-1 (PDCD1), 
Th-CTX also expressed GZMB, GZMH, and GNLY (Fig. 6A). Next, 
we verified the expression of these molecules at a protein level in 
patient samples ex vivo. As shown in Fig. 6 (B and C), both SLAMF7 
and PD-1 expression, even if heterogeneously, were detected directly 
ex vivo in NY-ESO-187–99/DR7–specific CD4 T cells from both 
PBLs and TILs/TILNs. PD-1 expression tended to be lower within 
circulating CD4 T cells in comparison to the tumor bed, at both 
transcriptomic and proteomic levels. In contrast, SLAMF7 tran-
scripts were comparable in both populations. A tendency toward 
lower SLAMF7 single-positive cells but higher double-positive 
SLAMF7+PD-1+ CD4 T cells in TILs/TILNs was observed, poten-
tially reflecting the higher activation state of these cells in the tumor 
microenvironment.
Similar results were obtained by analyzing tumor-specific CD4 
T cell clones, where expression of SLAMF7 and PD-1 was quite 
variable among patients with a range of expression of 6 to 61.5% 
and 23.1 to 75%, respectively. While PD-1 expression was high 
in both Th and Th-CTX clones, SLAMF7 and double-positive 
PD-1+SLAMF7+ were significantly enriched in cytolytic CD4 T cell 
clones (Fig. 6, D and E). SLAMF7 expression could be induced 
in vitro by exposure to recombinant IL-12 or to the histone deacetylase 
(HDAC) inhibitor Entinostat, previously reported to induce 
cytotoxicity in CD8 T cells (48) and to up-regulate cytotoxic-related 
genes in CD4 T cells (49), respectively (fig. S3E). Notably, EAT-2 
(EWS/FLI1 activated transcript), the requisite adaptor protein for 
SLAMF7 to mediate activation signaling, at least in NK cells, was 
higher in Th-CTX than Th clones (fig. S3F).
To establish the role of SLAMF7 and PD-1 in modulating the 
cytolytic function of CD4 T cells, standard 51Chromium release 
assays were performed, in the absence or presence of either an anti–
PD-1 antibody (Nivolumab) or an agonistic SLAMF7 antibody. 
Expression of SLAMF7 on target cells was verified, given the homo-
phylic nature of this receptor. Melanoma cell lines showed variable 
but consistent SLAMF7 expression with a mean of 27% positive 
cells (fig. S4B). While the percentage of specific lysis was not en-
hanced by the blockade of the PD-1/PD-L1 axis, engagement of 
SLAMF7 was able to trigger a modest but consistent significant 
increase of the lytic capacity of tumor-specific CD4 T cell clones 
(Fig. 6F), arguing for its therapeutic potential.
Data mining of The Cancer Genome Atlas (TCGA) RNA-seq 
dataset using SLAMF7 as a query revealed statistically significant 
association with favorable prognosis in melanoma (Fig. 6G), as well 
as in the other tumor types considered in the section below (fig. 
S5A). Although SLAMF7 may be expressed by various tumor- 
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cells, the association with favorable clinical outcome warrants 
further studies on the prognostic value of SLAMF7+ CD4 TILs. This 
correlative analysis was not possible in our patients’ cohort given 
the small sample size, the heterogeneity in terms of disease stage 
and treatment. However, notably, by further mining the TCGA 
RNA-seq dataset using neural cell adhesion molecule 1 (NCAM1), 
CD16, or NCR1 (Natural Cytotoxicity Triggering Receptor 1) as a 
query, no positive correlation was observed for NK cells and survival. 
Instead, a negative correlation was observed between NCAM1 and 
SLAMF7, suggesting that the main source of SLAMF in the tumor 
might not be NK cells (fig. S5, B and C).
Distribution of cytolytic CD4 T cells across cancer types 
and their relatedness to other T helper clusters
To verify to which extent our observations on cytotoxic CD4 T cells 
are conserved across tumor types, we investigated three additional 
































Clone Patient Th Th-CTX Alpha chain Beta chain
Clone-1 LAU331 x x hTRAV12-312-4_CAVGGRASGSARQLTFG_hTRAJ22 hTRBV19_CASSTRPGTEAFFG_hTRBJ01-1
Clone-2 LAU331 x hTRAV13-1_CAASNRFSGGYNKLIFG_hTRAJ04 hTRBV20_CSARDRIAVYNEQFFG_hTRBJ02-1
Clone-3 LAU1293 x hTRAV05_CAERAGTASKLTFG_hTRAJ44 hTRBV06-1_CASTLALGGGANEQFFG_hTRBJ02-1
Clone-4 LAU1293 x hTRAV10_CVVSPNQAGTALIFG_hTRAJ15 hTRBV06-2_CAISRDTRRGQPQHFG_hTRBJ01-5
Clone-5 LAU1293 x hTRAV12-2_CAVKKSSGSARQLTFG_hTRAJ22 hTRBV07-9_CASSPARDGGGNEQFFG_hTRBJ02-1
Clone-6 LAU1293 x hTRAV12-312-4_CALSPGAGNNRKLIWG_hTRAJ38 hTRBV09_CASSVGPDGSNQPQHFG_hTRBJ01-5
Clone-7 LAU1293 x x hTRAV13-1_CAAISNAGGTSYGKLTFG_hTRAJ52 hTRBV19_CASSTTGKRGEQYFG_hTRBJ02-7
Clone-8 LAU1293 x hTRAV17_CATDAMDSNYQLIWGAG_hTRAJ33 hTRBV05-1_CASSLSSGNYYGYTFG_hTRBJ01-2
Clone-9 LAU1293 x hTRAV22_CAVALIGFGNVLHCGSG_hTRAJ35 hTRBV30_CAWGPRGPNYSGNTIYFG_hTRBJ01-3
Clone-10 LAU1293 x x hTRAV23_CAAIRSSGSRLTFG_hTRAJ58 hTRBV16_CASSQSTVRYGYTFG_hTRBJ01-2
Clone-11 LAU1293 x hTRAV24_CAPVSNAGKSTFG_hTRAJ27 hTRBV09_CASSVGPSGGASELFFG_hTRBJ02-2
Clone-12 LAU1293 x hTRAV25_CAGPYTGANSKLTFG_hTRAJ56 hTRBV09_CASSVGPNGSNQPQHFG_hTRBJ01-5
Clone-13 LAU1352 x x hTRAV13-1_CAASRNFGNEKLTFG_hTRAJ48 hTRBV12-3_CASSLGRRGGPYNEQFFG_hTRBJ02-1
Clone-14 LAU1352 x hTRAV13-1_CAASSPSGGYQKVTFG_hTRAJ13 hTRBV10-1_CASSPNRVYGYTFG_hTRBJ01-2
Clone-15 LAU1352 x hTRAV24_CASISNTGNQFYFG_hTRAJ49 hTRBV09_CASSVAPSGVGTQYFG_hTRBJ02-5





Fig. 5. TCR repertoires of Th and Th-CTX CD4 T cells are polyclonal. PB-derived NY-ESO-187–99/DR7–specific CD4 T cell clones were discriminated as Th or Th-CTX based 
on results obtained with a standard 4-hour 51Chromium release assay. (A) Table listing the diverse clonotypes found in PB-derived NY-ESO-187–99/DR7 CD4 T cell clones 
from three patients with melanoma (LAU331, n = 8 clones; LAU1293, n = 15 clones; LAU1352, n = 9 clones). (B) Pies illustrating the relative abundance of each clonotypes 
as a whole (left), within Th (middle), or Th-CTX (right) clones. (C) Venn diagrams showing the distribution of unique and shared clonotypes frequencies between Th (gray) 
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Fig. 6. SLAMF7 as potential candidate to increase cytolytic potential of tumor-specific CD4 T cells. (A) tSNE 2D plot of scRNA-seq data representing the four CD4+ 
T cell clusters discriminating the cytolytic (blue), memory (green), cycling (yellow), and regulatory (gray) subsets and their expression of selected genes (SLAMF7, PDCD1, 
PRF1, GZMA, GZMB, GZMH, GZMK, GZMM, and granulysin). (B) Quantitative RT-PCR analysis of the indicated transcripts in ex vivo–sorted NY-ESO-187–99/DR7 CD4 T cells 
from either PB or TILs/TILNs. (C) Representative examples and cumulative analysis of direct ex vivo NY-ESO-187–99/DR7 CD4 T cell multimer staining combined with the 
evaluation of SLAMF7 and PD-1 expression of either PB or TILs/TILNs from patients with melanoma. (D) qRT-PCR analysis of the indicated transcripts in PB-derived 
NY-ESO-187–99/DR7 CD4 T cell clones discriminated as Th or Th-CTX. (E) Representative examples and cumulative analysis of SLAMF7 and PD-1 expression in PB-derived 
NY-ESO-187–99/DR7 CD4 T cell Th and-Th-CTX clones. (F) Standard 4-hour 51Chromium release assay, conducted with target tumor cell lines transduced with CIITA pulsed 
with the specific peptide in the presence or absence of Nivolumab (10 g/ml) (left) or agonistic anti-SLAMF7 antibody (5 g/ml) (right) and coincubated with antigen- 
specific CD4 T cell clones. Results are expressed as percentage of specific lysis of the target cells at 30:1 E:T ratios. (G) Kaplan-Meier plot depicting the survival probability 
and 95% confidence interval over time (years) for melanoma patients with high (blue) and low (black) SLAMF7 expression (data originated from TCGA). The difference 
between the two survival curves was assessed using a log-rank test. Statistics were performed using two-way ANOVA with Sidak’s post hoc test (B to D), nonparametric 
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published scRNA-seq datasets from breast cancer (BC) (50), head 
and neck cancer (51), and hepatocellular carcinoma (52), applying 
the same analysis pipeline as in Fig. 1. Th-CTX were observed in all 
tumor types analyzed, at population frequencies of 19.1, 2.8, 21.3, and 
39.6%, respectively (Fig. 7A). Moreover, transcriptomic comparison 
of the differentially expressed genes between the CD4_Cytolytic 
cluster and the other CD4 T cell clusters in these datasets demonstrated 
similar profiles, with the up-regulation of GZMA, CCL4/L2, and 
CCL5 in all cases. Other genes including GZMB, GZMK, IFNG, 
CST7, NKG7, EOMES, and CRTAM were up-regulated in Th-CTX in 
three of four cancer types. SLAMF7 was enriched in melanoma, BC, and 
hepatocellular carcinoma but not in head and neck cancer (Fig. 7B).
We next analyzed single-cell TCR sequences available for the 
patients with BC to evaluate the clonotype distribution in the different 
clusters and specifically within the CD4_Cytolytic cluster. Results 
showed the presence of 21 distinct clonotypes within the CD4_
Cytolytic cluster, suggesting the emergence of cytolytic CD4 T cells 
from a polyclonal population (Fig. 7C). Relative abundance of the 
CD4_Cytolytic cluster–specific TCR clonotypes revealed a heteroge-
neous distribution, with one preferably expanded clonotype (13.8%, 
clonotype red in Fig. 7C). This clonotype was among the most 
abundant detected in the entire CD4 T cell population. Moreover, 
2% of clonotypes within the CD4_Cytolytic cluster was shared with 
the entire CD4 T cell population, similarly to our observations on 
tumor-specific CD4 T cell clones (Fig. 5). Together, these results 
support the existence of cytotoxic CD4 T cells among TILs in various 
human tumor types.
DISCUSSION
The main finding in this work is the frequent existence of fully 
active, tumor-specific cytotoxic CD4 T cells in patients with cancer. 
Further, we identified the therapeutically targetable SLAMF7 molecule 
as a direct regulator of tumor-specific CD4 T cell cytotoxicity, high-
lighting a potential clinical relevance of triggering tumor-infiltrating 
CD4 T cell killers in immunotherapy. By building on preexisting 
knowledge on Th-CTX in cancer, we provide novel evidence on 
contact- and granule-dependent, delayed CD4 T cell cytotoxicity, 
visualized in real time and at the single-cell level.
Our unbiased scRNA-seq analysis in different patient datasets 
showed that Th-CTX share similarities with classical cytotoxic lym-
phocytes (10, 20). The direct ex vivo analysis of sorted tumor- 
specific CD4 T cells confirmed the presence of cytolytic-related 
transcripts in samples from both peripheral blood and TILs/TILNs. 
Notably, granzyme B expression was significantly down-regulated 
in the tumor bed compared to the peripheral blood. This might 
be due to an accumulation of Tregs in the TME (tumor micro-
environment), which would sequestrate the IL-2 necessary to in-
duce a cytolytic CD4 T cell profile, as recently reported (30). We 
also found preferential expression of PLEK, a gene previously re-
ported in precursors of Th-CTX (22), opening the question of the 
differentiation trajectories of these cells in vivo. The high levels 
of KLRG1 and the low levels of CD27 and CD28 (53), together 
with the significantly higher levels of CRTAM, argue for a late 
differentiation stage and potential long-term persistence of Th-
CTX in vivo. In this regard, the association of CADM1 expressing 
dendritic cells and CRTAM on CD8 T cells was reported as critical 
for the accumulation of antigen-specific CTLs and their subse-
quent proliferation in the draining LNs, suggesting a potential 
role of this molecule also in the priming and maintenance of Th-
CTX cells. Moreover, the recently reported expansion of a cyto-
toxic CD4 T cell cluster in supercentenarians hints for a role of 
this population in immune surveillance in elderly healthy donors.
In parallel to the cytolytic-related molecules, IFN, CCL4, and 
CCL5 were also enriched in Th-CTX cells. Recently, intratumoral 
NK cells producing CCL5 have been associated with the recruit-
ment of cross-priming cDC1s (54). Thus, it is tempting to speculate 
that tumor-infiltrating Th-CTX might also promote cDC1 migra-
tion to sustain CD8 T cell functions.
The main drivers of the cytolytic potential in human CD4 T cells 
remain unknown. One determinant might be the affinity of the 
TCR, as reported for CD8 T cells, where the affinity and binding 
strength of a TCR to its cognate pMHC correlates with T cell effec-
tor functions (55). Previous TCR repertoire analyses of CD4 T cells 
featuring cytolytic functions (22, 36) demonstrated a marked clonal 
expansion. Similarly, one TCR clonotype was significantly enriched 
and restricted to the Th-CTX cluster in the BC patient dataset, and 
it was also one of the most abundant clonotypes across all CD4 
T cells. The detection of a total of 21 different clonotypes within the 
cytolytic CD4 T cell cluster and the absence of unique TCRs in our 
helper and cytotoxic CD4 T cell clones rather suggest the emer-
gence of cytolytic CD4 T cells from an oligo/polyclonal population.
Alternatively, the concerted up- and down-regulation of master 
TFs (transcription factors) might be the key for the establishment of 
a stable Th-CTX phenotype. Several studies showed the induction 
of Th-CTX from Th2 (56), Th17, Treg (33, 57), or, more often, 
Th1-polarized T cell populations (28, 53, 58). We observed the 
up-regulation of EOMES and the down-regulation of ThPOK in the 
cytolytic CD4 cluster and a significant enrichment of RUNX3 ex-
pression among Th-CTX. These results are in line with the previ-
ously reported cross-regulation of RUNX3 and ThPOK during the 
acquisition of cytotoxic functions by human Th1 lymphocytes in 
the context of CMV infection (28) and in the reprogramming of 
CD4 T cells into intestinal intraepithelial cytolytic effectors (16, 30). 
Runx3 is a key factor in the development of the CD8 T cell lineage, 
by orchestrating the downstream activation of T-bet and Eomes 
(59, 60), which have also been suggested as defining cytolytic CD4 T cells 
(11,  25–27). However, no difference in T-bet expression was ob-
served in our comparison between helper versus cytotoxic CD4 T cells, 
suggesting for a dispensable role of this factor in Th-CTX functions. 
In agreement with our observations, T-bet deficient CD4 TILs in 
anti–CTLA-4–treated melanoma-bearing mice exhibited similar tumor 
rejection potency as their WT counterparts. These results illustrate 
the requirement of T-bet in IFN production but not in the cytolyt-
ic potential of this population, which was associated with a Blimp-1/
granzyme B axis (30). Intriguingly, the transcription factor ho-
molog of Blimp-1, called Hobit, was also associated with a cytotox-
ic potential in CD4 T cells during human cytomegalovirus infection 
(29). Yet, it was not specifically enriched in our dataset. Recently, 
it was reported that mCMV (murine cytomegalovirus)–infected 
mice deficient for the HDACs 1 and 2 in CD4 T cells developed a 
cytotoxic CD4 T cell program controlled by IFN– Janus kinase 
1/2–signal transducers and activators of transcription 1 signaling. Both 
murine and human CD4 T cells treated with short-chain fatty acids, 
known as metabolites acting as HDAC inhibitors, or Entinostat, 
up-regulated cytotoxic-related genes (49). Overall, these observa-
tions suggest a potential network of transcription factors and epigen-
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Furthermore, the coexpression of an array of activating/inhibitory 
receptors might be necessary for a full cytotoxic potential profile. In 
both the scRNA-seq datasets and in isolated patient CD4 T cells, we 
identified SLAMF7 and, to a lower extent, PD-1, in Th-CTX cells. 
A humanized anti-SLAMF7 antibody (Elotuzumab) and SLAMF7-
CAR T were already successfully used in the treatment of patients 
with multiple myeloma. Reported mechanisms potentially involved 
in the clinical efficacy imply the activation of NK cells, anti-
body-dependent cellular cytotoxicity, and inhibition of SLAMF7 
homophilic interactions in the bone marrow niche (46, 47). Instead, 
the relevance of SLAMF7 targeting in Th-CTX remains to be ad-
dressed in cancer. Our results showing an unleashing of the cyto-
toxic potential of CD4 T cells after agonistic engagement of SLAMF7 
open new therapeutic perspectives that warrant rapid testing in 
combination settings in patients with cancer. SLAMF7+ cytolytic 
CD4 T cells and their lytic function were previously described as a 








































































































































































































Fig. 7. Distribution of cytolytic CD4 T cells across cancer types and their relatedness to other T helper clusters. (A) tSNE 2D plot of scRNA-seq data representing the 
CD4+ T cell clusters discriminating the cytolytic (dark blue) and noncytolytic (gray) subsets across patients with melanoma, BC, head and neck cancer, and hepatocellular 
carcinoma. (B) Volcano plot analysis of gene expression changes in melanoma, BC, head and neck cancer, and hepatocellular carcinoma patients from Th-CTX compared 
to other Th clusters. Statistical power was assessed using Wilcoxon test [gray, P ≥ 0.01; blue, log fold change (logFC) > 0.25 and P < 0.01; black, logFC ≤ 0.25 and P < 0.01]. 
(C) 2D tSNE of scRNA-seq data representing the most abundant TCR clonotypes identified in the CD4_Cytolytic cluster in patients with BC, their relative abundance (left), 
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causal pathogenic link in the fibroinflammatory condition immuno-
globulin G4–related disease, through the lysis of MHCII+ endothe-
lial cells (61). In that regard, although we and others reported the 
expression of MHCII on tumor cells, the observed high frequency 
of MHCII-expressing stromal cells directly in situ in tumors further 
illustrates the need to evaluate the interactions of Th-CTX with 
these accessory cells, as previously shown in patients with multiple 
sclerosis (62) or in the context of helper CD4 T cell–mediated regu-
lation of angiogenesis in tumors (63, 64).
The direct assessment of the cytotoxic potential of Th-CTX 
demonstrated their primary dependence on cytotoxic granules, 
similar to classical cytotoxic lymphocytes (10), however with a dif-
ferent kinetic. Classical cytotoxic lymphocytes are known to form a 
lytic synapse with target cells within few minutes after the initial cell 
contact, resulting in the rapid apoptosis of the targets (65). These 
timing discrepancies might be due to the weaker affinity of CD4 
TCRs than those of CD8 T cells. Alternatively, this might be at-
tributed to the absence of a TCR-pMHC–stabilizing function of the 
CD4 coreceptor (66), as opposed to the CD8 molecule. Further, 
CD8 CTLs have demonstrated a capacity to kill outnumbering 
target cells, indicating a highly dynamic expression of the TCRs 
at the surface of the cell (65). In line with CD8 T cell data, our 
observations in the nanoscale array argue for the capacity of some 
CD4 T cells to lyse multiple targets, highlighting the potential 
presence of “superkiller cells” (65) also within the CD4 T cell pop-
ulation. Future evolution of these types of platforms will allow 
the retrieval of the cell(s) of interest. Invaluable phenotypic, tran-
scriptomic, and TCR analyses directly on patients’ blood or tumor tissue 
T cells will provide ultimate knowledge on the function of these cells.
Overall, we show, through an integrated large-scale transcrip-
tomic analysis and direct cell functional profiling down to the 
antigen-specific clonal and single-cell resolution level, that tumor- 
specific Th-CTX CD4 T cells represent an alternative/synergistic 
population to classical CD8 T cells, which carry cytotoxic capacities 
in addition to their helper/regulatory function. MHCI loss or 
down-regulation is a major tumor escape mechanism (67), which 
might be counteracted by the therapy-induced activation of MHCI- 
independent Th-CTX. Moreover, adoptive cell transfer therapy 
(ACT) of autologous, primary, or genetically modified CD4 T cells 
was shown to be both safe and effective in patients with metastatic 
solid tumors (2, 3, 9), highlighting the attractive potential of ACT 
using tumor-specific Th-CTX cells for personalized next-generation 
immunotherapy.
MATERIALS AND METHODS
scRNA-seq data source and processing
All the scRNA-seq data of the patients with melanoma were re-
trieved from the publication of Sade-Feldman et al. (37) [processed 
and normalized data were downloaded from the National Center 
for Biotechnology Information (NCBI) Gene Expression Omnibus 
(GEO) series GSE120575]. Cells from clusters G5 to G11 (n = 12,850), 
which correspond to T/NKT/NK cells according to the original 
study, were selected for the downstream analyses. Of these cells, 
CD4 T cells were identified as CD3E+CD4+ CD8A−CD8B− and CD8 
T cells as CD3E+CD4−CD8A+/CD8B+.
Following Seurat 2.3.4 pipeline, the normalized data were first 
scaled using Seurat method ScaleData. Variable genes (n = 533) 
were identified using Seurat method FindVariableGenes with the 
parameters x.low.cutoff = 0.01, x.high.cutoff = 14, y.cutoff = 1.5. 
The dimensionality reduction was performed using Seurat method 
RunPCA. The first 10 principal components were used to compute 
tSNE embedding using Seurat method RunTSNE with the parame-
ter seed.use = 12345. Four clusters of CD4 T cells were identified by 
shared nearest neighbor clustering using Seurat method FindClusters, 
with the parameter resolution = 0.3. Gene markers of these clusters 
were identified using Seurat method FindAllMarkers with parameters 
min.pct = 0.2, logfc.threshold = 1, only.pos = TRUE.
scRNA-seq data from patients with BC were retrieved from 
Azizi et al. (50). scRNA-seq data from patients with head and neck 
cancer were retrieved from Puram et al. (51). scRNA-seq data from 
patients with hepatocellular carcinoma were retrieved from (52). 
For the BC dataset, an additional quality control of cells was ap-
plied, because the downloaded dataset contained unprocessed 
matrix of UMI (unique molecular identifier) counts. In particular, 
cells having (i) less than 600 or more than 1500 genes, (ii) less than 
5000 or more than 30,000 UMIs, (iii) more than 15% of UMIs from 
mitochondrial protein-coding genes, and (iv) more than 50% of 
UMIs from ribosomal protein–coding genes were excluded. Data 
were normalized using a standard approach with the Seurat method 
NormalizeData.
In the head and neck cancer dataset, only T cells from primary 
tumors were kept for the downstream analyses. For both BC and 
head and neck cancer datasets, the identification of CD4/CD8 
T cells was identical to the approach described above (i.e., identifi-
cation of CD3+CD4+CD8− cells followed by clustering and cluster 
annotation based on known markers), while for the hepatocellular 
carcinoma, there was no additional filtering on CD4 and CD8 cells at 
the transcriptional level, because cells were sorted with fluorescence- 
activated cell sorter (FACS), only four outliers were removed. In 
total, we identified 7348 CD4 T cells in the BC dataset, 207 CD4 
T cells in head and neck cancer dataset, and 1159 CD4 T cells in 
hepatocellular carcinoma. Within those CD4 T cells, CD4_CTX 
cluster contained 203, 44, and 459 cells in BC dataset, head and neck 
cancer dataset, and hepatocellular carcinoma dataset, respectively.
TCR sequencing of T cells from BC dataset was downloaded 
from NCBI GEO series GSE114724 (GSM3148580 and GSM3148584). 
TCR was successfully sequenced for 99% of CD4 T cells. In our 
notation, clonotype is uniquely identified by its productive  and  
chain sequences. Cells of the same clonotype, therefore, have the 
same  and  chain sequences.
Gene ontology
Lists of the top 30 genes of each CD4 cluster were tested for over-
representation in GO gene sets linked to biological processes using 
the Panther online tool (68, 69). Overrepresentation analyses for 
each gene set were performed using default settings using a Fisher’s 
exact test. A false discovery rate–corrected P value threshold of 0.05 
was used (see complete data in tables S3 to S6).
Lymphocyte isolation from peripheral blood  
and tumor tissues
PBL and TILs or TILNs from patients with stage III/IV melanoma were 
obtained from the Department of Oncology, University Hospital 
[CHUV (Centre hospitalier universitaire vaudois), Lausanne, Switzerland; 
NCT00112229, NCT00002669, and NCT00002763; table S1], under 
the approval of the Lausanne University Hospital’s Institutional Re-
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and mononuclear cells were purified by density gradient centrifuga-
tion using Lymphoprep (STEMCELL). Isolated lymphocytes (from 
PBL, preimmunization TIL, or preimmunization TILN) were cryo- 
preserved in 90% fetal calf serum (FCS) (Gibco) and 10% dimethyl 
sulfoxide (DMSO) (Sigma-Aldrich) and stored in liquid nitrogen until 
further use.
Generation of enriched antigen-specific CD4 T cells 
and antigen-specific CD4 T cell clones
Antigen-specific CD4 T cells were evaluated either directly ex vivo 
or after one round of in vitro stimulation using fluorescent pMHCII 
multimers provided by the Peptide and Tetramer Core Facility, 
UNIL (University of Lausanne)–CHUV, Epalinges, Switzerland. 
CD4 T cells were incubated with optimal concentrations of fluo-
rescent pMHCII multimers in 8% RPMI culture medium for 45 min 
at room temperature following the addition of fluorescently labeled 
anti-CD3 and anti-CD4 antibodies and LIVE/DEAD Fixable Aqua 
Dead Cell Stain Kit (Thermo Fisher Scientific). Multimer-positive 
CD4 T cell populations were sorted using a FACSAria II or III sorter 
(BD Biosciences). Where indicated, multimer-negative CD4 T cells, 
naïve CD8 T cells (CD45RA+/CCR7+), and antigen-experienced 
CD8 T cells (CD45RA−/CCR7+, CD45RA−/CCR7−, and CD45RA+/
CCR7−) were also sorted from the same patient. Unstained cultures 
from the same patients or nonspecific HLA-matched pMHCII 
stainings were used as negative controls. Clones were obtained from 
T cells sorted from patients’ PBMCs by limiting dilution (0.5 cell 
per well) in Terasaki plates and cultured in RPMI medium with 8% 
HS (human serum) and recombinant human IL-2 (rh–IL-2) (100 U/ml), 
phytohemagglutinin (1 g/ml), and 10,000 irradiated allogenic feeder 
cells per well. Where indicated, CD4 T cell clones were exposed 
for 24 hours to rh–IL-12 (20 ng/ml; Peprotech) or 2 M Entinostat 
(MS-275, Selleckchem), before evaluation of SLAMF7 expression 
by flow cytometry.
Synthetic peptides
Peptides were synthesized at the Peptide and Tetramer Core Facility, 
UNIL-CHUV, Epalinges, Switzerland using INTAVIS synthesizers, 
using F-moc (fluorenylmethoxycarbonyl) for transient NH2-terminal 
protection. All peptides were >90% pure as indicated by analytic 
mass spectrometry and high-performance liquid chromatography. 
Lyophilized peptides were diluted in pure DMSO at 10 mg/ml, or aliquots 
of 1 mg/ml in 10% DMSO were prepared in PBS and stored at −80°C.
Tumor cell lines
Melanoma cell lines were established from metastatic surgery 
specimens from patients with melanoma from the Department of 
Oncology UNIL-CHUV and Ludwig Institute for Cancer Research, 
University of Lausanne (70) or provided by the Division of Immunology, 
Transplantation and Infectious Diseases, San Raffaele Scientific 
Institute, Milan. Tumor cell lines were cultured in 10% FCS RPMI.
Assessment of MHCII and SLAMF7 expression on melanoma 
tumor cell lines
Where indicated, tumor cell lines were treated with IFN (Peprotech), 
TNF (Peprotech), or both IFN and TNF at 50 or 200 U/ml 
for 48 hours before the flow cytometry analysis. Tumor cell 
lines were systematically labeled with fluorescein isothiocyanate 
(FITC) anti–HLA-DR, clone L243 (Abcam), BV421 anti–PD-1 
(BioLegend), phycoerythrin (PE)–Cy7 anti-SLAMF7 (BioLegend), 
PE-Cy7 anti–PD-L1 (BD Biosciences), and PE anti–PD-L2 (BD). 
Data were acquired on LSR II (BD Biosciences) and analyzed using 
FlowJo software (v.10.4.2).
Multiplex fluorescent IHC staining of metastatic melanoma 
tissue sections
Immunostainings were performed on 4-m formalin-fixed paraffin- 
embedded tissue sections from 18 melanoma cases, provided by the 
Institute of Pathology at the Lausanne University Hospital, CHUV. 
These cases were unrelated to the samples used for CD4 T cell func-
tional evaluation, precluding any correlative analyses between 
immunohistochemistry (IHC) results and CD4 T cell functional 
assessment in PBMCs/TILNs. Chromogenic IHC was performed 
using HLA-DR, MHCII (clone CR3/43, dilution 1:100; reference 
no. M0775) from Dako on the Ventana BenchMark XT system 
from Roche. For the multiplex fluorescent IHC on the Ventana 
Discovery Ultra Autostainer from Roche, apart from HLA-DR, 
SOX-10 (SRY-Box Transcription Factor 10), a melanoma marker 
(clone BC34, dilution 1:100; reference no. ACI 3099 A, C) from Bio-
care Medical and PD-L1 primary antibody (clone E1L3N, dilution 
1:200: reference no. 13684S) from Cell Signaling were used, followed 
by incubation with secondary horseradish peroxidase–labeled anti-
bodies. Tissue sections were counterstained with Spectral DAPI 
(4′,6-diamidino-2-phenylindole) from Akoya for 4 min. For the 
fluorescent detection with Opal dyes, an Opal 7-color Automation 
IHC kit (from Akoya, reference no. NEL821001KT) was used. 
An adjacent section was stained with hematoxylin and eosin (Ventana 
HE 600 system) for morphological reappraisal and to assist IHC in-
terpretation. The multiplex fluorescent panel was developed by 
ensuring that all antibodies stained robustly in a monoplex proto-
col, identifying only the target antigen of interest. A spectral library 
was created, preparing single-plex spectral control slides and an 
autofluorescence slide from the melanoma samples. Annotations 
were placed selectively in SOX-10+ areas, covering approximately 
two-thirds of the tissue sections, using the Phenochart 1.0.12 soft-
ware from Akoya, a whole-slide contextual viewer used for navi-
gation around slides for high- resolution multispectral acquisition. 
Multispectral images (MSI) were acquired using the Vectra 
3.0 automated quantitative pathology imaging system from Perkin-
Elmer. The whole-tissue slides were prescanned at a ×10 magnifica-
tion, and approximately 20 to 40 regions of interest images (number 
of fields in the PhenoptR analysis excel sheet) obtained with the 
20× objective were selected for the acquisition of high power (20×) 
MSI. In the Vectra, the scale bars of a 20× image were set as follows: 
1 pixel is calculated as (0.5 m) × (0.5 m) = 0.25 m2. To get the 
area in square millimeters, the area in pixels is divided by 4,000,000 
as 1 mm2 = 1,000,000 m2, and therefore, 0.25/1,000,000 is equal to 
1/4,000,000. For the data processing, algorithms for each case were 
designed, and the analysis was performed using the inForm 2.4.1 
software from Akoya. Regarding the frequency of HLA-DR+ cells, 
in the segmented tumor regions, it is calculated from SOX-10+ cells. 
In the segmented stromal region, it is calculated from the total 
number of cells given by the PhenoptR reports platform. The data 
were further treated with the Phenoptr Reports, an R-based addin 
for RStudio from Akoya.
Generation of CIITA-transduced tumor cell lines
The gene sequence of the human CIITA isoform 3 was provided by 
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Medicine, University of Geneva, Switzerland. The isoform 3 of the 
CIITA gene was inserted into a promoter modified retroviral vector 
pQCXIP (Clontech Corp) using the Age I–HF (high-fidelity) and 
Eco RI–HF restriction enzymes. The resulting hCIITA-pQCXIP 
plasmid DNA and the packaging plasmid DNA were introduced at 
ratio 1:1 into XL10-Gold ultracompetent Escherichia coli cells by 
calcium phosphate precipitation. Forty-eight hours after transfection, 
the green fluorescent protein reporter expression was examined 
by using a fluorescence microscope (Promega). Culture medium 
containing the virus was harvested and filtered to remove cellular 
debris. A portion of the infectious virions, mixed with polybrene 
(8 g/ml) to increase virus absorption within target lines, was added 
into a culture plate containing around 50 to 70% confluent GEFI 
and Me275 cell lines. Selection for drug resistance was initiated at 
48 hours after infection at 10 g/ml of blasticidin (Invitrogen). After 
selection, cell surface MHCII expression was assessed by flow cytometry 
using an anti–HLA-DR antibody (L243, BioLegend).
Chromium release assay and CD107a  
degranulation assay
The cytolytic potential of the blood-derived tumor-specific CD4 
T cells was assessed against HLA-matched melanoma cell lines (GEFI, 
GEFI-CIITA, GEFII, Me275, and Me275-CIITA), pretreated or not 
with IFN (50 U/ml; Peprotech) for 48 hours where indicated. Cells 
were labeled with 51Chromium (Amersham Biosciences) for 1 hour 
at 37°C. Labeled target cells were then incubated with effectors at 
the indicated effector to target (30:1,10:1, 3:1, and 1:1) ratio for 
4 hours at 37°C, in the presence or absence of a specific peptide. 
When indicated, addition of an inhibitor of perforin-mediated 
cytotoxicity, CMA at 100 nM (2 hours before incubation; Sigma- 
Aldrich), membrane-soluble Compound 20 at 20 M (30 min be-
fore incubation of target cells), a monoclonal anti–PD-1 antibody at 
10 g/ml (Opdivo; Bristol-Myers Squibb, CMA), an anti-SLAMF7 
antibody at 5 g/ml (BioLegend), or a transwell was added during 
the coculture. Supernatants were collected, and the released 51Cr 
was counted using a gamma counter (PerkinElmer, Boston, MA). 
Internal controls were included in each assay to measure the sponta-
neous release (target cells alone) and the maximal release (target 
cells with 1 M HCl). The percentage of specific lysis was calcu-
lated as follows: (experimental-spontaneous release)/(maximal- 
spontaneous) × 100. The resulting percentage of specific lysis 
enables the discrimination of the tumor-specific CD4 T cell clones 
as classical helpers (Th) or presenting dual helper and cytolytic 
functions (Th-CTX).
For the CD107a degranulation assay, Th-CTX were cocultured 
at 1:1 ratio for 4 hours with target cells, pulsed or not with the 
specific peptide, in the presence or absence of a FITC anti-CD107a 
antibody (BioLegend). After the coculture, cells were stained with 
PerCP-Cy5.5 anti-CD4 antibody (BioLegend). CD107a positivity 
was defined on CD4+ T cells, based on the FMO (fluorescence minus 
one) control.
High-throughput and time-resolved single-cell tumor 
recognition assay in picowell arrays
The picowell structures (35 m by 35 m by 50 m) for the confine-
ment of the cells within subnonaoliter volumes were fabricated by a 
replica molding process with PDMS as previously reported (42). A 
master mold was first prepared by standard photolithography on a 
10.16 cm silicon substrate. A direct laser writer (MLA 150, Heidel-
berg Instruments) patterned the spin-coated positive photoresist 
(AZ9221, Microchemicals GmbH), followed by a deep reactive Ion 
etching (AMS200, Alcatel Adixen). The picowell array was then 
oxidized by O2 plasma and bonded to the bottom of four-well 
-Slide (ibidi, Germany), forming an assembly for the following 
cell seeding. Immediately before use in cell-based assays, the picow-
ell array was reoxidized with O2 plasma and subsequently 
rinsed with cell media. Prestained tumor-specific CD4 or CD8 T 
cell clones (CellTrace Violet Cell Proliferation Kit, Invitrogen) 
and HLA-matched tumor cells (PKH26 and MINI26, Sigma-Al-
drich) were seeded sequentially into the picowell array. The seeding 
density was 1 × 105/ml and 1 × 105/ml, respectively. The assembly 
was incubated shortly after each step of cell seeding (10 min in the 
cell incubator) to allow sufficient cell deposition in the picowells. The 
medium was then replaced by 700 l of 10% FCS RPMI containing 
specific peptide (5 g/ml) and 5 M Incucyte Caspase-3/7 reagent 
(Sartorius). The prepared assembly was placed inside a microscope 
stage incubator that can provide essential cell culture conditions. 
The phenotype of the cells was distinguished with four channels 
(bright field, AF488, TRITC, and BV421) at 10-min intervals for a 
duration of 24 hours. Images were acquired using a Nikon Eclipse 
Ti-E inverted microscope and analyzed using the Nikon NIS-Ele-
ments (Advanced Research version 3.10, Nikon) software. The ac-
quired multichannel images were then converted to a video for 
the following feature extraction, which is done with an adapted 
version of DeepLabCut v2.2 [available at https://github.com/Dee-
pLabCut/DeepLabCut; original (43)].
Deep learning algorithm for automated and efficient  
image processing
To efficiently analyze the cell interactions within each well on the 
well plate, we used deep learning algorithms based on artificial neu-
ral network and trained the DeepLabCut to detect the well corners 
(lower left/upper right) as well as alive tumor cells, lysed tumor 
cells, alive T cells, and lysed T cells. Taking advantage of the fully 
convolutional architecture of DeepLabCut, we only annotated 3 × 3 
and 1 × 1 well crops from diverse videos. We found that the net-
work generalized well when processing the complete well plates. To 
train DeepLabCut, six types of features (well lower left corner, well 
upper right corner, alive tumor cell, lysed tumor cell, alive T cell, 
and lysed T cell) were labeled in 116 frames (of 3 × 3 or 1 × 1 well 
patches) selected from 15 videos in total (43). For interference, on 
novel videos, the trained network predicts the coordinates of all the 
detection in every frame. These coordinates were then used to im-
plement further screening process in Python to identify the wells 
with killing. The MFI of lysis was analyzed by measuring the inten-
sity within selected well areas in AF488 channel, and the time of 
lysis was defined as the maximum of the first derivative of the MFI 
curves, which represents the sharpest increase of caspase-3/7 activa-
tion when cell apoptosis was taking place.
Multiparametric flow cytometry analysis of cytolytic  
CD4 T cells
Tumor-specific CD4 T clones were stained systematically in PBS, 
0.2% bovine serum albumin (BSA), 5 mM EDTA, and 0.2% NaN3 with 
either (i) FITC anti-CD3 (BioLegend), BV605 anti-CD4 (BioLegend), 
ECD anti-CD8 (BD), PE-Cy7 anti-SLAMF7 (BioLegend), PerCP- 
Cy5.5 anti-CD57 (BioLegend), APC (allophycocyanin) anti-CD28 
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(BioLegend), and LIVE/DEAD Fixable Aqua Dead Cell Stain Kit 
(Thermo Fisher Scientific) or (ii) FITC anti-CD3 (BioLegend), BV605 
anti-CD4 (BioLegend), APC anti-TRAIL (BioLegend), PE anti-FasL 
(BioLegend), and LIVE/DEAD Fixable Aqua Dead Cell Stain Kit 
(Thermo Fisher Scientific) at 4°C for 30 min. Data were acquired on 
LSR II (BD Biosciences) and analyzed using FlowJo software (v.10.4.2).
Direct ex vivo enumeration of NY-ESO-187–99/DR7 CD4  
T cells
Enriched CD4 T cells were purified by positive selection using 
MACS isolation microbeads (Miltenyi) and stained directly ex vivo 
using a combination of fluorescent pMHCII multimers, as de-
scribed above and FITC anti-CD3 (BioLegend), BV605 anti-CD4 
(BioLegend), PE-Cy7 anti-SLAMF7 (BioLegend), BV711 anti–
PD-1 (BioLegend), and LIVE/DEAD Fixable Aqua Dead Cell Stain 
Kit (Thermo Fisher Scientific). Irrelevant multimers were used as 
negative controls. Data were acquired on LSR II (BD Biosciences) 
and analyzed using FlowJo software (v.10.4.2).
Intracellular granule and cytokine staining
Tumor-specific CD4 T clones were stimulated with serial dilutions 
of the specific peptides or left untreated for 6 hours at 37°C in the 
presence of brefeldin A (10 g/ml; Sigma-Aldrich). Cells were then 
stained in PBS, 0.2% BSA, 5 mM EDTA, and 0.2% NaN3 with BV421 
anti-CD3 (BioLegend) and BV605 anti-CD4 (BioLegend) at 4°C for 
30  min, fixed in PBS 1% formaldehyde, 2% glucose, and 5 mM 
NaN3 for 20 min at room temperature, and, lastly, stained in PBS, 
0.2% BSA, 5 mM EDTA, 0.2% NaN3, and 0.1% saponin (Sigma- 
Aldrich) with either (i) PE-Cy7 anti-IFN (BD Biosciences), PerCP- 
Cy5.5 anti-TNF (BioLegend), APC anti–IL-13 (BioLegend), and 
A700 anti–IL-17a (BioLegend) or (ii) PE anti-perforin (BioLegend), 
A700 anti-granzyme A (BioLegend), ECD anti-granzyme B (BD 
Biosciences), PerCP710 anti-granzyme K (eBioscience), APCeF660 
anti-granzyme M (eBioscience), and A488 anti-granulysin 
(eBioscience) for 30 min at 4°C before acquisition on an LSR II 
SORP (Beckman Coulter) flow cytometer. Percentages of granule/
cytokine- positive T cells were analyzed using FlowJo software 
(v.10.4.2). EC50 values were derived by dose-response curve analysis 
[log(agonist) versus response] using Prism software. Noncytokine 
clones, indicated in the added gray boxes, for which an EC50 value 
could not be determined accurately, were not included in the statis-
tical analyses.
SEB cytotoxicity assay
PBMCs were stained in PBS, 0.2% BSA, 5 mM EDTA, 0.2% NaN3 
with FITC anti-CD4 (BioLegend), and ECD anti-CD8a (Beckman 
Coulter) at 4°C for 30 min and sorted on a FACSAria II sorter (BD 
Biosciences). After sorting, cells were seeded for 3 days in the 
presence of aCD3/CD28 beads (Gibco) in RPMI 8% HS and rh-IL-2 
(100 U/ml), before using them in a single cell cytotoxicity assay on 
the high-throughput nanobiosensor (see above). Individual target 
cells were seeded in the nanowells, and then they were incubated 
with SEB (1 g/ml; Sigma-Aldrich) for 30 min. Cells were then 
washed, and individual T cells were seeded and monitored over 
24 hours.
RNA purification and RT-qPCR
Total RNA was isolated from either directly ex vivo sorted highly 
pure NY-ESO-187–99/DR7 CD4 T cells, multimer-negative CD4 
T cells, naïve CD8 T cells (CD45RA+/CCR7+), and antigen-experienced 
CD8 T cells (CD45RA−/CCR7+, CD45RA−/CCR7−, and CD45RA+/
CCR7−), stained in PBS, 0.2% BSA, 5 mM EDTA, 0.2% NaN3 with 
BV421 anti-CD45RA (BioLegend), and Alexa Fluor 700 anti-CCR7 
(BioLegend), or tumor-specific CD4 T cell clones using the TRIzol 
reagent according to the manufacturer’s instructions (Invitrogen, 
Carlsbad, CA, USA). The final preparation of RNA was considered 
DNA and protein free if the ratio of spectrophotometer (NanoDrop, 
Thermo Fisher Scientific, Carlsbad, CA, USA) readings at 260/280 nm 
was ≥1.7. Isolated mRNA was reverse-transcribed using the iScript 
cDNA Synthesis Kit (Bio-Rad Laboratories, Watford, UK) accord-
ing to the manufacturer’s protocol. The quantitative polymerase 
chain reaction (qPCR) was carried out in the Applied Biosystems 
7900HT Fast Real-Time PCR Sequence Detection System (Applied 
Biosystems) with specific primers (hPRF1, 5′-GACTGCCTGACT-
GTCGAGG-3′ and 5′-TCCCGGTAGGTTTGGTGGAA-3′; hGZMA, 
5′-CCCTATCCATGCTATGACCCA- 3′ and 5′-AGTATCGGAC-
CAAGATGCACTAT-3′; hGZMB, 5′-TACCATTGAGTTGTGC-
GTGGG-3′ and 5′-GCCATTGTTTCGTCCATAGGAGA-3′; hGNLY, 
5′-CCTGTCTGACGATAGTCCAAAAA-3′ and 5′-GACCTC-
CCCGTCCTACACA-3′; hTHPOK, 5′-TGATGGCCTACCTA-
AGCTCCC-3′ and 5′-CATGTGGCGAGGCAGTTTG-3′; hRUNX3, 
5′-AGCACCACAAGCCACTTCAG-3′ and 5′-GGGAAGGAGC-
GGTCAAACTG-3′; hFOXP3, 5′-GTGGCCCGGATGTGAGAAG-3′ 
and 5′-GGAGCCCTTGTCGGATGATG-3′; hTBET, 5′-GGTTGC-
GGAGACATGCTGA-3′ and 5′-GTAGGCGTAGGCTCCAAGG-3′; 
hGATA3, 5′-GCCCCTCATTAAGCCCAAG-3′ and 5′-TTGTG-
GTGGTCTGACAGTTCG-3′; hRORC, 5′-CTGGGCATGTC-
CCGAGATG-3′ and 5′-GAGGGGTCTTGACCACTGG-3′; hEOMES, 
5′-CTGCCCACTACAATGTGTTCG-3′ and 5′-GCGCCTTTGT-
TATTGGTGAGTTT-3′; hBLIMP1, 5′-TGGAAGATGAAAGGG-
CATTG-3′ and 5′-CATGGCTTGGCTCACAATTT-3′; hSLAMF7, 
5′-ACAACCCCTCTTGTCACCATA-3′ and 5′-CCCACATAGTA 
GATCCCTGAGTC-3′; hPDCD1, 5′-CCAGGATGGTTCT-
TAGACTCCC-3′ and 5′-TTTAGCACGAAGCTCTCCGAT-3′; 
hEAT-2, 5′-CCGTGTTTCTCTCTGAAGATTCG-3′ and 5′-AGA-
CAGCGAGTCGATACCAG-3′) using KAPA SYBR FAST qPCR 
Kits (KAPA Biosystems Inc., MA). All reverse transcription qPCR 
(RT-qPCR) reactions were performed in duplicate and amplified 
simultaneously with a nontemplate control blank for each primer 
pair to control for contamination or for primer dimerization, as 
well as a housekeeping gene (2-microglobulin) to normalize and 
determine the Ct values, using the 2−Ct formula.
TCR sequencing
mRNA was isolated from CD4 T cell clones derived from patients’ 
PBMCs using the Dynabeads mRNA DIRECT Purification Kit 
(Thermo Fisher Scientific/Ambion). First-strand cDNA was synthe-
sized using oligo(dT) (Promega) and the Superscript III (Thermo 
Fisher Scientific). TCR sequencing was performed as previously 
described in (71).
Survival analysis using TCGA data
The correlation between the SLAMF7 expression level and survival 
of patients with cancer was performed by using TCGA RNA-seq 
data available on the Human Protein Atlas website (www.proteinatlas.
org). We obtained [FPKM (Fragments Per Kilobase of sequence 
per Million mapped)] values of SLAMF7 in samples from mela-
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squamous cell carcinoma (N = 499), and liver hepatocellular carci-
noma (N = 365 patients), as well as vital status and survival time 
information for each patient. The classification of patients into high 
or low expression level of SLAMF7 was performed by using a differ-
ent cutoff for each cancer type (i.e., we used the default cutoff value 
proposed in the Human Protein Atlas): The cutoff was 0.77 FPKM 
for melanoma, 1.5 FPKM for BC, 6.63 FPKM for head and neck 
cancer, and 1.33 FPKM for liver cancer. The difference between the 
high- and the low-SLAMF7 survival curves was assessed using a 
log-rank test separately for each cancer type.
Statistical analysis
Statistical analyses were performed as indicated in the legend for 
each experiment using GraphPad Prism (version 8.2.1). For all 
analyses, a P < 0.05 was statistically significant and labeled by *, 
<0.05 by **, <0.001 by ***, and <0.0001 by ****. Not statistically 
significant differences were left unlabeled.
SUPPLEMENTARY MATERIALS
Supplementary material for this article is available at http://advances.sciencemag.org/cgi/
content/full/7/9/eabe3348/DC1
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